Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DTGM fusion protein in relapsed/refractory AML
NCT00003840Phase 2Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Oct 2000
- Primary completion
- Sep 2002
- Modality
- Recombinant Proteins and Enzymes, Immunotoxins
- Countries
- 1
01
Overview
A Phase 2 trial of DTGM in acute myeloid leukemia (AML), sponsored by Wake Forest University Health Sciences. Started Oct 2000; status: completed.
02
Drugs
DTGM
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00003840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003840.